Prior-duty update: Noridian A60217 R2
Published November 4, 2026 · Coverage October 25–31, 2026, Pacific · Medium priority
Noridian’s October 29 Jurisdiction E notice says revision R2 to billing and coding article A60217 adds 0665U to Group 1 for specified liver-disease biomarker testing, effective October 1, 2026. Noridian cautions that a code’s inclusion does not automatically mean coverage. This is a potential update to the October 11 finding GC-2026-0134; compare the current article and LCD with the earlier version before treating it as a material change. The current complete article, LCD and registry details remain open.
Applicability and suggested action: Affected molecular diagnostics and billing teams can compare the article, associated LCD and any applicable registry requirements before changing workflows; a listed code alone does not establish coverage.
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Medicare & Medicaid Sweep report →